Posted by Michael Wonder on 16 Jun 2020
FDA approves first treatment for adult onset Still’s disease, a severe and rare disease
16 June 2020 - The U.S. Food and Drug Administration today approved Ilaris (canakinumab) injection for the treatment of active Still’s disease, including adult-onset Still’s disease.
Ilaris was previously approved for systemic juvenile idiopathic arthritis in patients aged 2 years and older.
Ilaris was granted priority review designation, under which the FDA’s goal is to take action on an application within six months where the agency determines that the drug, if approved, would significantly improve the safety or effectiveness of treating, diagnosing or preventing a serious condition.
